

Listing of Claims:

This listing of the claims will replace all prior versions, and listings, of claims in this Application.

1-105. (Canceled)

106. (Currently Amended) A method for transporting a non-steroidal anti-inflammatory drug through human or animal skin or mucous membranes, comprising administering to the skin or a mucous membrane of a human or an animal a vesicular composition comprising:

- (a) a vesicle consisting essentially of:
 - i) one or more phosphatidyl cholines;
 - ii) a salt of one or more non-steroidal anti-inflammatory drugs; and
 - iii) one or more of phenol, cresol or benzyl alcohol,

wherein an aqueous medium is contained within the vesicle and wherein said vesicle has a size of 50 to 500 nm; and

- (b) the aqueous medium.

107. (Previously Presented) The method of claim 106, wherein the aqueous medium is a buffer.

108. (Previously Presented) The method of claim 107, wherein the buffer has a pH of 3 to 12.

109. (Previously Presented) The method of claim 108, wherein the buffer has a pH of 5 to 9.

110. (Previously Presented) The method of claim 109, wherein the buffer has a pH of 6 to 8.

111. (Canceled)

112. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a natural phosphatidyl choline.

113. (Previously presented) The method of claim 112, wherein at least one of the one or more phosphatidyl cholines is from egg, soybean, coconut, olive, saffron, sunflower, linseed, whale fat, primrose, or primula.
114. (Previously presented) The method of claim 106, wherein at least one of the one or more phosphatidyl cholines is a synthetic phosphatidyl choline.
115. (Previously presented) The method of claim 106, wherein at least one of the one or more non-steroidal anti-inflammatory drugs is diclofenac or ibuprofen.
116. (Currently Amended) The method of claim 106, wherein the vesicle further consists essentially of one or more consistency modifiers and/or one or more ~~[[,]]~~ antioxidants.
117. (Previously presented) The method of claim 116, wherein the consistency modifier is a hydrogel.
118. (Previously presented) The method of claim 116, wherein the antioxidant is probucol, tocopherol, BHT, ascorbic acid, or desferroxamine.
119. (Canceled)
120. (Previously Presented) The method of claim 106, wherein up to 50 mg of the vesicular composition are administered per cm² of skin surface.
121. (Previously presented) The method of claim 106, wherein the salt is a lithium, sodium, potassium, cesium, rubidium, ammonium, monomethyl, dimethyl, trimethylammonium or ethylammonium salt.
122. (New) The method of claim 106, wherein the vesicle has a size of 75 to 400 nm.
123. (New) The method of claim 122, wherein the vesicle has a size of 100 to 200 nm.